Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 USD | +5.11% | +4.52% | -17.78% |
May. 02 | Vor Bio Appoints Fouad Namouni to its Board of Directors | CI |
Mar. 21 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.43M | Capitalization | 120M |
---|---|---|---|---|---|
Net income 2024 * | -102M | Net income 2025 * | -115M | EV / Sales 2024 * | - |
Net Debt 2024 * | 16.29M | Net cash position 2025 * | 52.11M | EV / Sales 2025 * | 47.6 x |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.3
x | Employees | 168 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.84% |
1 day | +5.11% | ||
1 week | +7.56% | ||
Current month | +7.56% | ||
1 month | -14.35% | ||
3 months | -19.21% | ||
6 months | -7.04% | ||
Current year | -17.78% |
Managers | Title | Age | Since |
---|---|---|---|
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
Nathan Jorgensen
DFI | Director of Finance/CFO | 47 | 20-04-30 |
Chief Tech/Sci/R&D Officer | 51 | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 20-07-29 |
Matt Patterson
CHM | Chairman | 52 | 20-10-19 |
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +3.45% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.85 | +5.11% | 564,003 |
24-05-07 | 1.76 | +0.57% | 576,854 |
24-05-06 | 1.75 | -2.78% | 129,704 |
24-05-03 | 1.8 | +2.27% | 162,062 |
24-05-02 | 1.76 | -0.56% | 242,306 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.78% | 120M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- VOR Stock